TSVT - 2seventy bio, Inc.
IEX Last Trade
3.05
0.030 0.984%
Share volume: 2,464
Last Updated: Fri 27 Dec 2024 08:30:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$3.02
0.03
0.99%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-07 | 2023-03-16 | 2023-05-10 | 2023-08-14 | 2023-11-14 | 2024-03-07 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 787.406 M | 708.744 M | 656.665 M | 742.437 M | 705.713 M | 640.806 M | 565.426 M | 511.051 M | |
| Current Assets | 383.890 M | 349.417 M | 300.882 M | 389.817 M | 333.665 M | 277.254 M | 237.765 M | 212.842 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 25.963 M | 26.307 M | 34.612 M | 49.887 M | 50.828 M | 26.635 M | 20.776 M | 18.674 M | |
| Short Term Investments | 25.963 M | 26.307 M | 34.612 M | 49.887 M | 50.828 M | 26.635 M | 20.776 M | 18.674 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 357.927 M | 323.110 M | 266.270 M | 339.930 M | 282.837 M | 250.619 M | 216.989 M | 181.382 M | |
| Total Non-current Assets | 403.516 M | 359.327 M | 355.783 M | 352.620 M | 372.048 M | 363.552 M | 327.661 M | 298.209 M | |
| Property Plant Equipment | 39.199 M | 46.650 M | 55.735 M | 59.153 M | 61.023 M | 60.681 M | 58.150 M | 38.234 M | |
| Other Assets | 303.966 M | 291.735 M | 279.276 M | 272.854 M | 268.312 M | 262.441 M | 258.101 M | 253.558 M | |
| Intangible Assets | 7.656 M | 7.479 M | 7.302 M | 7.125 M | 6.948 M | 6.771 M | 6.594 M | 6.417 M | |
| Goodwill | 12.056 M | 12.056 M | 12.056 M | 12.056 M | 12.056 M | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 787.406 M | 708.744 M | 656.665 M | 742.437 M | 705.713 M | 640.806 M | 565.426 M | 511.051 M | |
| Total liabilities | 408.422 M | 385.564 M | 346.199 M | 341.113 M | 338.218 M | 334.384 M | 310.126 M | 303.612 M | |
| Total current liabilities | 99.014 M | 79.897 M | 79.794 M | 76.929 M | 66.895 M | 68.008 M | 59.779 M | 60.406 M | |
| Accounts Payable | 6.685 M | 7.983 M | 7.208 M | 13.399 M | 6.274 M | 5.307 M | 6.028 M | 8.801 M | |
| Other liabilities | 43.496 M | 43.177 M | 7.397 M | 8.712 M | 19.617 M | 18.486 M | 6.334 M | 3.135 M | |
| Current long term debt | 10.730 M | 10.798 M | 11.164 M | 11.482 M | 11.872 M | 12.267 M | 12.660 M | 13.006 M | |
| Long term debt | 265.912 M | 262.490 M | 259.008 M | 255.472 M | 251.706 M | 247.890 M | 244.013 M | 240.071 M | |
| Other liabilities | 43.496 M | 43.177 M | 7.397 M | 8.712 M | 19.617 M | 18.486 M | 6.334 M | 3.135 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 378.984 M | 323.180 M | 310.466 M | 401.324 M | 367.495 M | 306.422 M | 255.300 M | 207.439 M | |
| Common stock | 38.381 M | 38.573 M | 38.843 M | 43.468 M | 50.966 M | 51.179 M | 51.491 M | 52.071 M | |
| Retained earnings | -202.625 M | -270.504 M | -293.647 M | -340.668 M | -382.757 M | -454.395 M | -511.217 M | -563.890 M |